CHEK vs. AIKI, OTRK, PPBT, ABVC, NXGL, RDHL, CNTG, MBOT, KPRX, and BTCY
Should you be buying Check-Cap stock or one of its competitors? The main competitors of Check-Cap include AIkido Pharma (AIKI), Ontrak (OTRK), Purple Biotech (PPBT), ABVC BioPharma (ABVC), NEXGEL (NXGL), RedHill Biopharma (RDHL), Centogene (CNTG), Microbot Medical (MBOT), Kiora Pharmaceuticals (KPRX), and Biotricity (BTCY). These companies are all part of the "medical" sector.
AIkido Pharma (NASDAQ:AIKI) and Check-Cap (NASDAQ:CHEK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.
Check-Cap's return on equity of -18.21% beat AIkido Pharma's return on equity.
Check-Cap received 269 more outperform votes than AIkido Pharma when rated by MarketBeat users. Likewise, 65.95% of users gave Check-Cap an outperform vote while only 63.92% of users gave AIkido Pharma an outperform vote.
AIkido Pharma has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Check-Cap has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.
AIkido Pharma has higher revenue and earnings than Check-Cap. Check-Cap is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.
10.9% of AIkido Pharma shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, AIkido Pharma had 1 more articles in the media than Check-Cap. MarketBeat recorded 1 mentions for AIkido Pharma and 0 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.67 beat AIkido Pharma's score of 0.00 indicating that AIkido Pharma is being referred to more favorably in the media.
Summary
AIkido Pharma beats Check-Cap on 10 of the 13 factors compared between the two stocks.
Get Check-Cap News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHEK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHEK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Check-Cap Competitors List
Related Companies and Tools
